European Medicines Agency

Profile narrative

The European Medicines Agency (EMA) is the European Union’s body responsible for the scientific evaluation, supervision and safety monitoring of medicines for human and veterinary use. It provides a centralised authorization procedure that allows a single marketing assessment to be valid across all EU member states and, by extension, the European Economic Area, thereby facilitating access to medicines for a population of over 447 million people. The agency examines dossiers submitted by pharmaceutical companies, assesses the benefits and risks of each product, and issues opinions that inform the European Commission’s decision on granting a marketing authorisation. In addition to the centralised route, the EMA supports national authorities through mutual recognition and decentralised procedures, offers scientific advice to developers during the research and development phase, and prepares guidelines that harmonise standards for clinical trials, manufacturing and pharmacovigilance. Its remit covers innovative medicines, generic and biosimilar products, advanced therapies such as gene‑cell treatments, vaccines and veterinary medicinal products, and it also oversees orphan medicines and medicines for paediatric use through dedicated committees.

The EMA’s distinguishing attribute lies in its role as the EU’s central regulator for medicines, which enables it to harmonise evaluation standards across diverse national systems and to act as a focal point for public health protection. It hosts several scientific committees, including the Committee for Medicinal Products for Human Use (CHMP), the Pharmacovigilance Risk Assessment Committee (PRAC), the Committee for Orphan Medicinal Products (COMP) and the Paediatric Committee (PDCO), each providing expert opinions that shape EU‑wide policy. The agency’s expertise in evaluating complex biological products was highlighted in December 2020 when unauthorized actors accessed and altered confidential Pfizer/BioNTech COVID‑19 vaccine data before leaking it, an incident that underscored both the sensitivity of the information it handles and the importance of its data‑security measures. Beyond evaluation, the EMA contributes to international harmonisation efforts with agencies such as the U.S. Food and Drug Administration and Japan’s Pharmaceuticals and Medical Devices Agency, promotes research and innovation, and maintains transparency by publishing meeting minutes, assessment reports and safety updates.

Structurally, the EMA is an independent EU agency established by EU regulation and financed through a combination of European Union contributions and fees paid by industry for services such as scientific advice, authorization procedures and inspections. It reports to the European Parliament, the Council of the European Union and the European Commission, and its headquarters are located in Amsterdam, the Netherlands. The agency operates as a supranational body without a parent company or subsidiary structure; its accountability rests directly with the EU institutions, and it functions under a governance framework that includes a Management Board and an Executive Director who oversees day‑to‑day operations.

Incidents

1 incident linked to this organisation.